

| | | |
|--|---|--|
| RoM = robust average | AV = assigned value | Dmax = acceptable percent difference |
| SD = standard deviation | CRV = certified reference value | LL = lower limit |
| CV = coefficient of variation | RV = reference value | UL = upper limit |
| Ntot = total number of participants | CVE = consensus value from experts | Neva = number of evaluated participants |
| Nout = number of results excluded before calculation | CVP = consensus value from all participants | Nsuc = number of successful participants |
| | CVPG = consensus value from participants groups | Srel = success (relative) |
| | U_{AV} = expanded uncertainty of the assigned value ($k = 2$) | |

| Test | [unit] | Comparability | | | | | Comparability | | | | | | |
|----------------------------------|--------|---------------|------|--------|------------------|------------------|---------------|----------|------------------|------|------|------------------|------------------|
| | | RoM | SD | CV [%] | N _{tot} | N _{out} | AV | U_{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} |
| (253) CD 3+ T lymphocytes | | | | | 30 | | | | | | 30 | 29 | 97% |
| Samples and groups | [%] | | | | | | | | | | | | |
| Sample A | | 73,9 | 1,7 | 2,3 | 30 | CVP | 74 | 0,41 | 7% | 68,8 | 79,2 | 30 | 30 100% |
| All results | | 73,9 | 1,7 | 2,3 | 30 | 0 | | | | | | 30 | |
| Sample B | | 73,8 | 1,5 | 2,1 | 30 | CVP | 74 | 0,37 | 7% | 68,8 | 79,2 | 30 | 29 97% |
| All results | | 73,8 | 1,5 | 2,1 | 30 | 0 | | | | | | 30 | |
| (254) CD 4+ T lymphocytes | | | | | 30 | | | | | | 30 | 29 | 97% |
| Samples and groups | [%] | | | | | | | | | | | | |
| Sample A | | 40,7 | 1,3 | 3,1 | 30 | CVP | 41,1 | 0,28 | 10% | 36,9 | 45,3 | 30 | 30 100% |
| All results | | 40,7 | 1,3 | 3,1 | 30 | 0 | | | | | | 30 | |
| Sample B | | 42,2 | 1,8 | 4,3 | 30 | CVP | 42,4 | 0,36 | 10% | 38,1 | 46,7 | 30 | 29 97% |
| All results | | 42,2 | 1,8 | 4,3 | 30 | 0 | | | | | | 30 | |
| (255) CD 8+ T lymphocytes | | | | | 30 | | | | | | 30 | 30 | 100% |
| Samples and groups | [%] | | | | | | | | | | | | |
| Sample A | | 22,9 | 1,5 | 6,4 | 30 | CVP | 23,2 | 0,39 | 17% | 19,2 | 27,2 | 30 | 30 100% |
| All results | | 22,9 | 1,5 | 6,4 | 30 | 0 | | | | | | 30 | |
| Sample B | | 28,9 | 1,4 | 4,9 | 30 | CVP | 29 | 0,33 | 17% | 24 | 34 | 30 | 30 100% |
| All results | | 28,9 | 1,4 | 4,9 | 30 | 0 | | | | | | 30 | |
| (256) B lymphocytes | | | | | 30 | | | | | | 30 | 30 | 100% |
| Samples and groups | [%] | | | | | | | | | | | | |
| Sample A | | 17,3 | 1,5 | 8,9 | 30 | CVP | 17,4 | 0,31 | 30% | 12,1 | 22,7 | 30 | 30 100% |
| All results | | 17,3 | 1,5 | 8,9 | 30 | 0 | | | | | | 30 | |
| Sample B | | 9,36 | 0,97 | 10 | 30 | CVP | 9,16 | 0,18 | 30% | 6,41 | 12 | 30 | 30 100% |
| All results | | 9,36 | 0,97 | 10 | 30 | 0 | | | | | | 30 | |
| (257) NK cells | | | | | 30 | | | | | | 30 | 28 | 93% |
| Samples and groups | [%] | | | | | | | | | | | | |
| Sample A | | 7,34 | 1,4 | 18 | 30 | CVP | 7,23 | 0,33 | 36% | 4,62 | 9,84 | 30 | 29 97% |
| All results | | 7,34 | 1,4 | 18 | 30 | 0 | | | | | | 30 | |
| Sample B | | 15,7 | 1,6 | 10 | 30 | CVP | 15,5 | 0,33 | 26% | 11,4 | 19,6 | 30 | 29 97% |
| All results | | 15,7 | 1,6 | 10 | 30 | 0 | | | | | | 30 | |